N-Cyano-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N''-[(3-methylphenyl)-methyl]guanidine | 441756-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-Cyano-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N''-[(3-methylphenyl)-methyl]guanidine
• 英文别名: N-Cyano-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N"-[(3-methylphenyl)-methyl]guanidine；1-cyano-3-[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]-2-[(3-methylphenyl)methyl]guanidine
• CAS: 441756-66-7
• 化学式: C₂₀H₁₉N₅O₂
• 分子量: 361.403
• InChiKey: CNXPTQRQVLTOQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  95.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3-甲氧基-4-(1,3-噁唑)苯胺 以 乙腈 为溶剂， 生成 N-Cyano-N'-[3-methoxy-4-(5-oxazolyl)phenyl]-N''-[(3-methylphenyl)-methyl]guanidine
  参考文献：
  名称：

  Novel guanidine-Based inhibitors of inosine monophosphate dehydrogenase

  摘要：

  A series of novel guanidine-based small molecule inhibitors of inosine monophosphate dehydrogenase (IMPDH) was explored. IMPDH catalyzes the rate determining step in guanine nucleotide biosynthesis and is a target for anticancer, immunosuppressive and antiviral therapy. The synthesis and the structure-activity relationships (SARs), derived from in vitro studies, for this new series of inhibitors is given. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00600-5

文献信息

• Angiogenesis inhibitors
  申请人：THE JOHNS-HOPKINS UNIVERSITY

  公开号：EP2803357A2

  公开（公告）日：2014-11-19

  Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.

  本文描述了抑制血管生成和治疗或预防与血管生成有关的疾病或紊乱（或其症状）的方法，其中向受试者施用抗血管生成化合物。
• ANGIOGENESIS INHIBITORS
  申请人：THE JOHNS-HOPKINS UNIVERSITY

  公开号：EP1765336A2

  公开（公告）日：2007-03-28
• Angiogenesis Inhibitors
  申请人：Liu Jun

  公开号：US20080193499A1

  公开（公告）日：2008-08-14

  Described herein are methods of inhibiting angiogenesis, and treating or preventing a disease or disorder (or symptoms thereof) associated with angiogenesis, wherein an anti-angiogenesis compound is administered to a subject.
• US6420403B1
  申请人：——

  公开号：US6420403B1

  公开（公告）日：2002-07-16
• US8980930B2
  申请人：——

  公开号：US8980930B2

  公开（公告）日：2015-03-17